A method to determine the mode of binding for GCPII inhibitors using bio-layer interferometry

Abstract The rapid dilution of the enzyme-inhibitor complex assay to monitor the recovery of enzyme activity is a well-established assay to determine the reversibility of inhibition. Our laboratory has previously employed this method to ascertain the reversibility of known glutamate carboxypeptidase II (GCPII)-targeting agents. Due to the tedious and time-consuming nature of the assay, we sought to develop a facile method to determine the reversibility of well-characterized GCPII inhibitors using bio-layer interferometry (BLI). The results from the BLI assay are in agreement with the rapid dilution method. Herein, we report for the first time, a rapid, novel real-time BLI method to determine reversibility of inhibition.

[1]  Paul D Benny,et al.  PSMA‐targeted SPECT agents: Mode of binding effect on in vitro performance , 2013, The Prostate.

[2]  Il-Hoon Cho,et al.  Label-free, needle-type biosensor for continuous glucose monitoring based on competitive binding. , 2013, Biosensors & bioelectronics.

[3]  W. Davis,et al.  Chemoaffinity capture of pre‐targeted prostate cancer cells with magnetic beads , 2012, The Prostate.

[4]  Jeonghoon Lee,et al.  Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate. , 2012, Bioorganic & medicinal chemistry letters.

[5]  J. Bryan,et al.  A phosphoramidate‐based prostate‐specific membrane antigen‐targeted SPECT agent , 2012, The Prostate.

[6]  Tiancheng Liu,et al.  A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. , 2010, Bioorganic & medicinal chemistry letters.

[7]  Andreas Lingel,et al.  Hedgehog Pathway Antagonist 5E1 Binds Hedgehog at the Pseudo-active Site , 2010, The Journal of Biological Chemistry.

[8]  Ximing J. Yang,et al.  Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. , 2009, Human pathology.

[9]  Tiancheng Liu,et al.  Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. , 2008, Biochemistry.

[10]  Cheryl A. Tajon,et al.  The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. , 2007, Bioorganic & medicinal chemistry.

[11]  T. Tsukamoto,et al.  Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. , 2007, Drug discovery today.

[12]  Tiancheng Liu,et al.  Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography. , 2006, Protein expression and purification.

[13]  Dianqing Wu,et al.  Prostate-Specific Membrane Antigen Regulates Angiogenesis by Modulating Integrin Signal Transduction , 2006, Molecular and Cellular Biology.

[14]  J. Neale,et al.  NAAG peptidase inhibitors and their potential for diagnosis and therapy , 2005, Nature Reviews Drug Discovery.

[15]  V. Reuter,et al.  Prostate-specific membrane antigen is produced in tumor-associated neovasculature. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  W. Heston.  Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. , 1997, Urology.

[17]  J. Coyle,et al.  Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.